Global clinical data services company MedAvante has appointed Dr Michael Ropacki as vice president of research and development.
Dr Ropacki joins MedAvante from Johnson & Johnson, where he served as clinical research neuroscience director in its Janssen research and development arm.
Prior to this, he was medical director, global medical affairs for Janssen’s Alzheimer’s disease immunotherapy unit from June 2011 to May 2013.
He also brings experience as associate director and principal clinical scientist at Johnson & Johnson’s biotech Centocor, which he first joined as a clinical scientist in 2004.
Paul Gilbert, MedAvante’s chief executive officer, said: “Michael Ropacki is widely recognised for the groundbreaking trial methodology he has implemented for registries and prospective cohort studies.
“He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition to MedAvante’s scientific leadership team.”